简介：癌症，特别是肺癌，是全球医疗保健面临的重大挑战。非小细胞肺癌 (NSCLC) 占病例的 85%。患者经常在西医治疗的同时寻求替代疗法，如中医。本研究调查了台湾非小细胞肺癌患者辅助中医治疗的生存结果和成本效益。方法：利用国家健康保险研究数据库进行2000年至2018年的回顾性队列研究，以2007年至2013年诊断的NSCLC患者为对象，按1：5的比例进行倾向评分匹配后，对接受和不接受中医辅助治疗的患者进行比较。进行了生存结果、成本效益和敏感性分析。结果：本研究共纳入43122例NSCLC患者，其中5.76%接受中药辅助治疗。死亡风险与辅助中药治疗之间没有显着相关性，直到181-365天的辅助治疗可以降低死亡风险（HR = 0.88，95% CI：0.80-0.98）。成本效益分析显示，增量成本效益比为新台币880,908元/年。结论：辅助中药治疗，尤其是持续 181-365 天时，可显着降低 IV 期 NSCLC 患者的死亡风险。成本效益与支付意愿阈值一致，表明经济效益。版权所有 © 2024 Tang、Kuo、Kung 和 Tsai。

Introduction: Cancer, particularly lung cancer, is a significant global healthcare challenge. Non-Small Cell Lung Cancer (NSCLC) constitutes 85% of cases. Patients often seek alternative therapies like Chinese medicine alongside Western treatments. This study investigates the survival outcomes and cost-effectiveness of adjunctive Chinese medicine therapy for NSCLC patients in Taiwan. Methods: We utilized the National Health Insurance Research Database in a retrospective cohort study from 2000 to 2018, focusing on NSCLC patients diagnosed between 2007 and 2013. After propensity score matching 1:5 ratio, then compared patients with and without adjunctive Chinese medicine therapy. Survival outcomes, cost-effectiveness, and sensitivity analyses were conducted. Results: The study involved 43,122 NSCLC patients with 5.76% receiving adjunctive Chinese medicine. There is no significant associated between the risk of death and adjuvant Chinese medicine therapy until 181-365 days of adjuvant treatment could reduce the risk of death (HR = 0.88, 95% CI: 0.80-0.98). Cost-effectiveness analysis showed an incremental cost-effectiveness ratio of 880,908 NT$/year. Conclusion: Adjunctive Chinese medicine therapy, particularly when administered for 181-365 days, significantly reduced the mortality risk among stage IV NSCLC patients. The cost-effectiveness aligns with willingness-to-pay thresholds, indicating economic benefit.Copyright © 2024 Tang, Kuo, Kung and Tsai.